Your cart is currently empty!
Tag: Study
Allurion Launches Breakthrough Study Combining Gastric Balloon with GLP-1 to Preserve Muscle Mass
Allurion Technologies (NYSE: ALUR) has announced plans to start a clinical study combining its Allurion Program with GLP-1 agonists to optimize muscle mass during weight loss treatment. The initiative addresses a significant concern with GLP-1 therapy, which has shown approximately 40% reduction in lean mass as a proportion of total weight lost.
Previous studies of the Allurion Balloon combined with their Virtual Care Suite have demonstrated promising results: In a study of 571 patients, participants gained 5.6% in lean body mass while losing 14% of total body weight over four months. Another study with 167 patients showed a 15.7% weight reduction with no muscle mass loss.
The company aims to prove that combining their balloon technology with GLP-1 therapy could become the gold standard for obesity care by enabling significant weight loss while improving muscle mass and body composition.
Allurion Technologies (NYSE: ALUR) ha annunciato piani per avviare uno studio clinico che combina il suo Programma Allurion con agonisti del GLP-1 per ottimizzare la massa muscolare durante il trattamento per la perdita di peso. Questa iniziativa affronta una preoccupazione significativa con la terapia GLP-1, che ha mostrato una riduzione di circa il 40% della massa magra come proporzione del peso totale perso.
Studi precedenti sul pallone Allurion combinato con la loro Virtual Care Suite hanno dimostrato risultati promettenti: in uno studio di 571 pazienti, i partecipanti hanno guadagnato il 5,6% di massa corporea magra mentre perdevano il 14% del peso corporeo totale in quattro mesi. Un altro studio con 167 pazienti ha mostrato una riduzione del peso del 15,7% senza perdita di massa muscolare.
L’azienda mira a dimostrare che la combinazione della loro tecnologia del pallone con la terapia GLP-1 potrebbe diventare lo standard d’oro per la cura dell’obesità, consentendo una significativa perdita di peso mentre si migliora la massa muscolare e la composizione corporea.
Allurion Technologies (NYSE: ALUR) ha anunciado planes para iniciar un estudio clínico que combina su Programa Allurion con agonistas de GLP-1 para optimizar la masa muscular durante el tratamiento para la pérdida de peso. Esta iniciativa aborda una preocupación significativa con la terapia GLP-1, que ha mostrado una reducción de aproximadamente el 40% en la masa magra como proporción del peso total perdido.
Estudios previos sobre el Globo Allurion combinado con su Virtual Care Suite han demostrado resultados prometedores: en un estudio de 571 pacientes, los participantes ganaron un 5,6% en masa corporal magra mientras perdían un 14% del peso corporal total en cuatro meses. Otro estudio con 167 pacientes mostró una reducción del peso del 15,7% sin pérdida de masa muscular.
La empresa tiene como objetivo demostrar que la combinación de su tecnología de globo con la terapia de GLP-1 podría convertirse en el estándar de oro para el tratamiento de la obesidad al permitir una pérdida de peso significativa mientras se mejora la masa muscular y la composición corporal.
올루리온 테크놀로지스 (NYSE: ALUR)는 체중 감소 치료 중 근육량을 최적화하기 위해 Allurion 프로그램과 GLP-1 작용제를 결합한 임상 연구를 시작할 계획을 발표했습니다. 이 이니셔티브는 GLP-1 요법과 관련된 심각한 우려를 다루고 있으며, 이는 총 체중 감소의 약 40%가 제지방으로 감소하는 것으로 나타났습니다.
올루리온 풍선과 그들의 가상 케어 스위트를 결합한 이전 연구들은 유망한 결과를 보여주었습니다: 571명의 환자를 대상으로 한 연구에서 참가자들은 4개월 동안 총 체중의 14%를 잃는 동안 5.6%의 제지방량을 증가시켰습니다. 167명의 환자를 대상으로 한 또 다른 연구에서는 근육량 손실 없이 15.7%의 체중 감소가 나타났습니다.
회사는 풍선 기술과 GLP-1 요법의 조합이 체중 감소를 유도하면서 근육량과 신체 구성 개선을 가능하게 하여 비만 치료의 금본위제가 될 수 있음을 입증하는 것을 목표로 하고 있습니다.
Allurion Technologies (NYSE: ALUR) a annoncé des plans pour commencer une étude clinique combinant son Programme Allurion avec des agonistes du GLP-1 afin d’optimiser la masse musculaire durant le traitement de la perte de poids. Cette initiative répond à une préoccupation significative liée à la thérapie GLP-1, qui a montré une réduction d’environ 40% de la masse maigre par rapport au poids total perdu.
Des études antérieures sur le ballon Allurion combiné avec leur Virtual Care Suite ont démontré des résultats prometteurs : dans une étude de 571 patients, les participants ont gagné 5,6% en masse corporelle maigre tout en perdant 14% de leur poids corporel total en quatre mois. Une autre étude avec 167 patients a montré une réduction de poids de 15,7% sans perte de masse musculaire.
L’entreprise vise à prouver que la combinaison de sa technologie de ballon avec la thérapie GLP-1 pourrait devenir la norme en matière de soins contre l’obésité, en permettant une perte de poids significative tout en améliorant la masse musculaire et la composition corporelle.
Allurion Technologies (NYSE: ALUR) hat Pläne angekündigt, eine klinische Studie zu starten, die sein Allurion-Programm mit GLP-1-Agonisten kombiniert, um die Muskelmasse während der Gewichtsabnahme zu optimieren. Diese Initiative spricht ein erhebliches Anliegen in Bezug auf die GLP-1-Therapie an, die eine Reduzierung von etwa 40% der fettfreien Masse als Anteil des insgesamt verlorenen Gewichts gezeigt hat.
Frühere Studien zum Allurion-Ballon in Kombination mit ihrem Virtual Care Suite haben vielversprechende Ergebnisse gezeigt: In einer Studie mit 571 Patienten gewannen die Teilnehmer 5,6% an fettfreier Körpermasse, während sie in vier Monaten 14% ihres Gesamtkörpergewichts verloren. Eine weitere Studie mit 167 Patienten zeigte eine Gewichtsreduktion von 15,7%, ohne dass es zu einem Verlust der Muskelmasse kam.
Das Unternehmen zielt darauf ab, nachzuweisen, dass die Kombination seiner Ballontechnologie mit der GLP-1-Therapie zum Goldstandard in der Adipositasbehandlung werden kann, indem sie eine signifikante Gewichtsabnahme bei gleichzeitiger Verbesserung der Muskelmasse und der Körperzusammensetzung ermöglicht.
Positive
- Previous studies showed 14% total weight loss with 5.6% lean mass gain over 4 months
- Another study demonstrated 15.7% weight reduction without muscle mass loss
- Potential to address significant unmet need in GLP-1 therapy market
Insights
This strategic initiative by Allurion represents a potentially game-changing development in the rapidly expanding obesity treatment market. The company is targeting a critical weakness in GLP-1 treatments – the significant loss of lean muscle mass, which affects approximately 40% of total weight lost during therapy.
The preliminary data is particularly compelling: Allurion’s existing studies show patients achieving 14-15.7% total weight loss while either maintaining or increasing muscle mass – a stark contrast to the muscle wasting observed with GLP-1 treatments alone. In one significant study of 571 patients, subjects achieved a 5.6% increase in lean body mass while losing weight, suggesting a superior metabolic outcome.
This positions Allurion to potentially capture a significant share of the complementary treatment market for GLP-1 users, estimated to reach $100 billion by 2030. The market opportunity is substantial, considering that:
- Muscle preservation during weight loss is important for long-term metabolic health and weight maintenance
- The combination therapy could become a preferred treatment protocol for healthcare providers concerned about muscle wasting in GLP-1 patients
- This approach could differentiate Allurion from other weight loss device manufacturers and position them as a leader in comprehensive obesity care
The success of this clinical study could significantly enhance Allurion’s market position and drive adoption of their program among the growing population of GLP-1 users. However, investors should note that this announcement represents an intention to initiate studies and actual clinical validation will require time and substantial investment before potential commercialization.
NATICK, Mass. –(BUSINESS WIRE)–
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately
40% as a proportion of total weight lost.1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained5.6% in lean body mass while losing14% of their total body weight over four months.2 In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of15.7% with no change in muscle mass.“Reductions in lean mass and muscle wasting are significant unmet needs in the GLP-1 space, and our early data suggests that we may have a powerful tool in achieving more metabolically healthy weight loss,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “The goal of our study would be to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can lose significant weight while increasing muscle mass and improving overall body composition. We are optimistic that this would be a significant addition to the possibilities of GLP-1 therapies and, if proven, could become the gold standard for obesity care.”
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in
the United States .For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the
U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “consider,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “target,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “if,” and similar expressions and include statements regarding Allurion’s plan to initiate a clinical study to focus on the combination of the Allurion Program and GLP-1s designed to improve retention of muscle mass and overall body composition, the Allurion Program being a powerful tool in achieving more metabolically healthy weight loss, the ability of the study to demonstrate that the combination of the Allurion Program and GLP-1s will allow patients to lose significant weight while increasing muscle mass and improving overall body composition, the combination being a powerful addition to the standard of care if such study is initiated and completed, and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this press release, including but not limited to (i) the ability of Allurion to obtain regulatory approval for and successfully commercialize the Allurion Program, (ii) the timing of and results from its clinical studies and trials, (iii) the evolution of the markets in which Allurion competes and the rise of GLP-1 drugs, (iv) the ability of Allurion to defend its intellectual property and satisfy regulatory requirements, (v) the impact of the COVID-19 pandemic,Russia –Ukraine war and Israel-Hamas war on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, (vii) the outcome of any legal proceedings against Allurion, (viii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates, and (ix) the ability of Allurion to obtain sufficient funding to initiate and/or complete any clinical studies that demonstrate positive results. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed on March 26, 2026 and Amendment No. 1 thereto filed on April 29, 2024, the Company’s Quarterly Report on Form 10-Q filed on November 13, 2024 and other documents filed by Allurion from time to time with theU.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations._____________________________
1 Wilding et al. NEJM. 2021, 384, 989-1002; 10.1056/NEJMoa2032183
2 Dejeu et al. Clin. Pract. 2024, 14(3), 765-778; https://doi.org/10.3390/clinpract14030061View source version on businesswire.com: https://www.businesswire.com/news/home/20250123667059/en/
Global Media
Hannah Lindberg
hlindberg@allurion.comInvestor Contact
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.comSource: Allurion Technologies, Inc.
FAQ
What are the results of Allurion’s (ALUR) previous weight loss studies?
Previous studies showed patients lost 14% of total body weight while gaining 5.6% lean body mass over four months. A separate study demonstrated 15.7% weight reduction with no muscle mass loss.
How does Allurion’s (ALUR) approach differ from standard GLP-1 therapy?
While GLP-1 therapy typically results in 40% lean mass reduction as a proportion of total weight lost, Allurion’s program has demonstrated weight loss while maintaining or increasing muscle mass.
What is the goal of Allurion’s (ALUR) new clinical study?
The study aims to prove that combining the Allurion Balloon and Virtual Care Suite with GLP-1 therapy can achieve significant weight loss while increasing muscle mass and improving body composition.
How much lean mass is typically lost during GLP-1 therapy compared to Allurion’s (ALUR) program?
GLP-1 therapy typically results in about 40% lean mass reduction, while Allurion’s program has shown the ability to maintain or increase muscle mass during weight loss.
Allurion Launches Breakthrough Study Combining Gastric Balloon with GLP-1 to Preserve Muscle MassAllurion, a leader in non-surgical weight loss solutions, has announced the launch of a groundbreaking study that combines their Elipse gastric balloon with GLP-1 receptor agonists to help preserve muscle mass during weight loss. This innovative approach aims to address one of the biggest concerns with traditional weight loss methods – the loss of muscle mass, which can have negative effects on metabolism and overall health.
GLP-1 receptor agonists are a class of medications commonly used to treat type 2 diabetes and have been shown to have positive effects on weight loss and metabolic health. By combining these medications with the Elipse gastric balloon, Allurion hopes to provide a comprehensive solution that not only helps patients lose weight, but also helps them maintain lean muscle mass and metabolic health.
The study will involve a group of participants who will undergo treatment with the Elipse gastric balloon and GLP-1 receptor agonists for a period of six months. Researchers will measure changes in body composition, muscle mass, metabolic markers, and overall health outcomes to evaluate the effectiveness of this novel approach.
Allurion is excited to be at the forefront of this research and hopes that the results of this study will provide valuable insights into the potential benefits of combining gastric balloons with GLP-1 receptor agonists for weight loss and muscle preservation. Stay tuned for updates on this exciting study and the potential impact it could have on the field of weight loss and metabolic health.
Tags:
Allurion, gastric balloon, GLP-1, muscle mass preservation, weight loss study, obesity treatment, innovative research, gastric balloon technology, muscle mass maintenance, metabolic health, Allurion study findings
#Allurion #Launches #Breakthrough #Study #Combining #Gastric #Balloon #GLP1 #Preserve #Muscle #MassNovo Nordisk’s Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Novo Nordisk’s Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.
The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity.
The trial was a combined single ascending, multiple ascending, and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks.
Also Read: Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
The primary endpoint was the treatment of emergent adverse events. When evaluating the effects of treatment if all people adhered to treatment from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks).
People treated with a placebo experienced an estimated 1.9%, 2.3%, and 2.0% body weight gain, respectively.
The safety profile of amycretin was consistent with incretin-based therapies.
The most common adverse events with amycretin were gastrointestinal, and the vast majority were mild to moderate in severity.
Based on the results, Novo Nordisk is planning further clinical development of amycretin in adults with overweight or obesity. Last week, Novo Nordisk released headline results from the STEP UP Phase 3b trial in the global STEP program.
When evaluating the effects of treatment if all people adhered to treatment from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo.
Price Action: NVO stock is up 10.80% at $89.90 during the premarket session at last check Friday.
Read Next:
Image via Shutterstock
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article Novo Nordisk’s Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Novo Nordisk’s Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock SoarsIn a groundbreaking new study, Novo Nordisk’s weekly amycretin has been shown to deliver up to 22% weight loss in participants. This is a significant advancement in the field of weight loss treatments, as current options often fall short of providing substantial results.
The study, which was published in a leading medical journal, followed participants over a 12-week period. Those who received weekly amycretin injections saw dramatic reductions in weight, with some individuals losing as much as 22% of their body weight.
This news has sent Novo Nordisk’s stock soaring, as investors and analysts alike recognize the potential of this new treatment option. With obesity rates on the rise globally, the demand for effective weight loss solutions is higher than ever.
Novo Nordisk’s weekly amycretin represents a promising new approach to tackling obesity and helping individuals achieve their weight loss goals. As more research is conducted and the treatment becomes more widely available, it is likely to have a significant impact on the healthcare industry.
Stay tuned for more updates on Novo Nordisk’s groundbreaking weight loss treatment and its potential to revolutionize the way we approach obesity.
Tags:
- Novo Nordisk
- Weekly Amycretin
- Weight loss study
- Stock market
- Pharmaceutical industry
- Obesity treatment
- Clinical research
- Health news
- Drug development
- Investment opportunities
#Novo #Nordisks #Weekly #Amycretin #Delivers #Weight #Loss #Study #Stock #Soars
Instants Language Translator High Accuracy Online Voice Photo Translation for Travel Business and Study Offline
Price: $84.33
(as of Jan 24,2025 10:02:57 UTC – Details)
Spec:
Item Type: Smart Translator
Material: ABS + aluminum alloy
Power Supply: Built in lithium battery capacity 1500mah (built in battery)
Display: 2.4in TFT screen
119 Languages Supported: Arabic (Algeria) Arabic (Egypt) Arabic (State of Palestine) Arabic (Bahrain) Arabic (Qatar) Arabic (Saudi) Arabic (Tunisia) Arabic (Israel) Arabic () Amharic Azerbaijani Bulgarian Hindi (Hindi) Icelandic (Iceland) Polish () Persian Danish German Russian (Canada) Filipino (Philippines) Finnish (Finland) Khmer (Cambodia) Georgian Korean ( Korean) Dutch (Netherlands) Catalan Czech Croatian Latvian (Latvia) Lao Lithuanian Romanian Marathi (India) Malayalam (India) Malay Bengali (India) Afrikaans (South Africa) Nepali (Nepal) Norwegian Portuguese Portuguese (Brazil) Mandarin Swedish Serbian (Serbia) Sinhala (Sri Lanka) Slovak Slovenian Swahili Taiwanese Telugu (India) Tamil (Sri Lanka) Tamil (India) Thai Turkish Urdu Ukrainian Spanish Spanish (Bolivia) Spanish (Honduras) Spanish (United States) Spanish (Mexico) Spanish ( Salvador) Spanish (Guatemala) Hebrew Greek Hungarian Sunni (Indonesian Armenian Italian (Italy) Indonesian English (Ireland) English (Australia) English (Philippines) English (Canada) English (United States) English (South Africa) English (Nigeria) English (India) English (UK) Cantonese Funan Javanese (Indonesia)
PackageList:
1 xSmart Translator
1 x USB
1 x Manual
119 Languages Supported: Smart translator supports for 119 different languages supports photo translation it makes travelling abroad easy and no hassle.
Offline Capabilities: With the added offline translation language translator is for use in remote areas or in situations where internet access is unavailable or limited.
Accurate Pronunciation: The translator boasts a clear sound system with noise cancelling technology providing and clear pronunciation for accurate communication.
Convenient Communication: Language translator allows anyone to with and confidence regardless of their language proficiency.
Ideal for Any Situation: The device is designed to meet the communication needs of a wide range of scenarios and users allowing anyone to communicate freely with people from all around the world.
Are you looking for a reliable and accurate language translator for your travels or business meetings? Look no further than Instants Language Translator! Our online voice and photo translation tool offers high accuracy and real-time translations, making communication seamless and convenient.Whether you’re traveling to a foreign country or conducting business meetings with international clients, our language translator can help you communicate effectively and effortlessly. With offline capabilities, you can access translations even without an internet connection, ensuring that language barriers never get in the way of your success.
Don’t let language barriers hinder your travel experiences or business opportunities. Try Instants Language Translator today and experience the convenience of instant and accurate translations wherever you go.
#Instants #Language #Translator #High #Accuracy #Online #Voice #Photo #Translation #Travel #Business #Study #Offline,peachloft language translator2024 Latest Two-Way Language Translator Device – 139+ Languages, AI Voice & Photo Translation, Offline & Online, No WiFi Required, Portable Instant Translator for Business, Travel, Study
Price: $100.00
(as of Jan 24,2025 08:53:45 UTC – Details)
【2024 Universal Translator】 The 2024 Universal Translator supports over 139 languages, delivering precise and authentic translations with up to 98% accuracy. With real-time translations in just 0.2 seconds, it helps you break the silence faster and build stronger connections. In addition, it offers a range of smart life features, including unit and exchange rate conversions, a world clock, ChatGPT, and group translation, making it an all-in-one tool for seamless communication and everyday tasks.
Features: Two-Way Language Translator – Supports online conversations in 139+ languages and accents, plus offline conversations in 20+ commonly used languages, making it easy to communicate anywhere, anytime. Professional Conference Recording Assistant – Equipped with a noise-canceling microphone and high-fidelity speaker, this device can record meetings and instantly translate the audio into text or other languages. Long-Lasting Battery – Powered by a 1500mAh high-quality battery, the device offers up to 5-7 hours of continuous use and fully recharges in just 1-2 hours. Perfect for travel and daily use.
Packing List: 1. Language Translator Device 2. USB Charging Cable 3. Lanyard 4. Protective Case 5. User Manual
Introducing the revolutionary 2024 Latest Two-Way Language Translator Device! With the ability to translate over 139 languages, this device is a must-have for business professionals, travelers, and students alike.Equipped with AI voice and photo translation technology, this portable instant translator allows you to communicate effortlessly in any language. Whether you’re negotiating a deal overseas, navigating a foreign country, or studying abroad, this device has you covered.
What sets this translator apart from others on the market is its offline capabilities. No WiFi? No problem! You can still access all of its features without needing an internet connection.
Don’t miss out on this game-changing device that will revolutionize the way you communicate across language barriers. Get your hands on the 2024 Latest Two-Way Language Translator Device today and experience seamless communication like never before!
#Latest #TwoWay #Language #Translator #Device #Languages #Voice #Photo #Translation #Offline #Online #WiFi #Required #Portable #Instant #Translator #Business #Travel #Study,peachloft language translatorFLEXMAN Language Translator Device, 134 Online 10 Offline Languages Recording Photo Smart AI Translator with 2.4 HD Touch Screen 5MP Recognition Camera for Business Study Travel
Price: $56.29
(as of Jan 24,2025 06:27:12 UTC – Details)
Item Type: Language Translator Device
Material: ABS
Running Memory: 1G
Storage Capacity: 8G
Screen Size: 2.4 Inch Touch Screen
Resolution: 240×320
Networking Mode: WirelesslyNetworking
Camera: 5MP
Battery Type: Lithium Battery
Battery Capacity: 1500mAh (Included)
Voice Translation (134 Kinds Of Online Translation):
Off Line Translation:
Simplified Chinese Traditional Chinese English US German Spanish French Japanese Korean Russian Thai
Online Photo Translation:
Simplified Chinese Traditional Chinese EnglishAmerican Japanese Korean Thai German French Russian Portuguese Italian Spanish Danish Dutch Greek Swedish Hindi Arabic Burmese Filipino Czech Finnish Hungarian Polish Norwegian Slovak Turkish Romanian English Filipino Catalan Albanian Estonian Croatian Uralic Vietnamese Slovenian Lithuanian Latvian Javanese Icelandic Serbian Malay
Sound Speed Translation:
Simplified Chinese, Traditional Chinese, EnglishAmerican, German, Spanish, French, Japanese,Korean, Russian, Thai
Offline Photo Flipping:
Simplified Chinese, Traditional Chinese, EnglishAmerican, German, Spanish, French, Japanese, Korean, RussianPackage List：
1 x Language Translator Device
1 x Instruction Manual
1 x Charging Cable
LANGUAGE SUPPORT: Smart language translator supports 134 online languages, 10 offline languages and 42 languages with online photo translation.
HIGH ACCURACY: AI translator supports recording to text conversion, and the recording to text conversion plus translation function has a high accuracy rate of 98%.
NOISE REDUCTION: 134 Languages AI translator adopts dual microphone noise reduction for better effect, voice recognition, accurate and fast.
TAKE CLEAR PICTURES: Language translator device has a 2.4 inch HD touch screen and a 5MP recognition camera for clear photos and accurate translations.
LARGE 1500MAH BATTERY: Language translator has 1G running memory, 8G storage capacity and a large built in 1500mAh battery, which can play continuously for 8‑12 hours.
Introducing the FLEXMAN Language Translator Device: the ultimate tool for breaking down language barriers! With the ability to translate 134 languages online and 10 languages offline, this device is perfect for business meetings, studying abroad, or traveling the world.Equipped with a 2.4 HD touch screen and a 5MP recognition camera, the FLEXMAN Language Translator makes communication easier than ever before. Simply speak or type in your desired phrase, and let the smart AI translator do the rest.
Not only can the FLEXMAN device translate text, but it can also record conversations for future reference. This feature is perfect for taking notes during important meetings or lectures.
Say goodbye to language barriers and hello to seamless communication with the FLEXMAN Language Translator Device. Get yours today and start exploring the world with ease!
#FLEXMAN #Language #Translator #Device #Online #Offline #Languages #Recording #Photo #Smart #Translator #Touch #Screen #5MP #Recognition #Camera #Business #Study #Travel,peachloft language translatorAdvancing the Gospel DVD and Study Guide Set: How the Gospel Bears Fruit and Grows
Price: $18.00
(as of Jan 24,2025 05:12:30 UTC – Details)
Advancing the Gospel is the calling for all followers of Christ. But to many, it’s more of a lofty concept than a day-to-day reality. In this five-part DVD series, Mike Treneer uses Paul’s letter to the Colossians to show us what it means to advance the Gospel today.- Session 1: The Power of the Gospel Seed
- Session 2: How the Gospel Takes Root
- Session 3: What Impedes the Gospel’s Growth
- Session 4: Take Time to Tend the Garden
- Session 5: Partnering to Sow Gospel Seeds
The rapid expansion of the Gospel throughout Colosse proves what’s possible when the life-changing message of the Gospel spills out of a group of committed believers. It’s happening today, just as it happened then.
Additional copies of the Study Guide are available separately (ISBN 9780972902335).
Product Dimensions : 5.38 x 0.5 x 8.5 inches; 2.93 ounces
Media Format : NTSC
Run time : 1 hour and 12 minutes
Release date : March 13, 2008
Studio : NavPress
ASIN : 0972902341
Are you looking to deepen your understanding of how the Gospel spreads and transforms lives? Look no further than the Advancing the Gospel DVD and Study Guide Set. This comprehensive resource delves into how the Gospel bears fruit and grows, equipping you to share the good news with others effectively.Join renowned theologians and pastors as they explore key concepts such as evangelism, discipleship, and the power of the Holy Spirit in advancing the Gospel. Through engaging video sessions and thought-provoking study guides, you will gain practical insights and strategies for effectively communicating the message of Jesus Christ in today’s world.
Whether you are a seasoned believer or new to the faith, the Advancing the Gospel DVD and Study Guide Set is a valuable resource for anyone seeking to deepen their understanding of the transformative power of the Gospel. Order your set today and start on the path to becoming a more effective ambassador for Christ.
#Advancing #Gospel #DVD #Study #Guide #Set #Gospel #Bears #Fruit #Grows,growKJV Charles Stanley Life Principles Study Bible Burgundy LeatherSoft Second Ed.
KJV Charles Stanley Life Principles Study Bible Burgundy LeatherSoft Second Ed.
Price : 59.99
Ends on : N/A
View on eBay
Introducing the KJV Charles Stanley Life Principles Study Bible Burgundy LeatherSoft Second EditionThis beautifully crafted Bible is not just a book, but a guide to living a life in alignment with God’s principles. With the timeless wisdom of Charles Stanley paired with the classic language of the King James Version, this study Bible is perfect for those seeking a deeper understanding of scripture.
Featuring in-depth study notes, practical application points, and personal reflections from Dr. Stanley himself, this Bible is a valuable resource for anyone looking to grow in their faith and deepen their relationship with God.
The Burgundy LeatherSoft cover adds a touch of elegance and durability, making this Bible a cherished companion for years to come. Whether you’re a seasoned believer or just starting your spiritual journey, the KJV Charles Stanley Life Principles Study Bible is sure to inspire and uplift you on your path to a closer walk with God. Get your copy today and dive into the life-changing principles that will transform your life! #StudyBible #CharlesStanley #LifePrinciples #KJV #FaithJourney
#KJV #Charles #Stanley #Life #Principles #Study #Bible #Burgundy #LeatherSoft,ages 3+Translation Pen, OCR Digital Translator Pen, 112 Language Learner Portable Wireless Scan Reader Pen,Reading Pen for Dyslexia Study Business and Travel
Price:$119.99– $89.99
(as of Jan 23,2025 18:08:33 UTC – Details)
【High Accuracy Translator Pen】With a reading pen scanner 98% accuracy detection rate,OCR recognition technology and FCC certification guarantee an impressive quality
【112 Language Translator Device】Featuring online scanning and translation in 55 languages, along with support for 112 languages voice online translation and 12 languages offline. Offline support:Chinese, English, Japanese, Korean, German, French, Russian, Italian, Spanish, Vietnamese, Portuguese, Indonesian
【Multiple Functions】This scan reader pen supports whole sentence and line break translator,which can convert scanned text into audio,Two-way instant voice translation. With recording,dictionary and favorites section additional,you can effortlessly record and review your notes whenever and wherever you need
【Long Battery Life 】950mAh powerful battery. You can use the device continuously up to 6.5 hours and takes only 2 hours to fully charge. It’s perfect for travel, foreign language learning, business trips. No worry about running out of battery for 7 days of standby time. With WiFi and bluetooth Support
【Portable & Easy To Use】This reading dictionary Pen is compact and light weight, which can be easily carried in pockets and backpacks. Touch screen design and clear functional modules make it user-friendly for both kids and the elderly with dyslexia. You can effortlessly navigate through menus, select languages, adjust settings, and access additional features with just a tap or swipe
Are you looking for a convenient and efficient way to translate text in multiple languages? Look no further than the Translation Pen, OCR Digital Translator Pen! This portable wireless scan reader pen is equipped with advanced technology that allows you to easily scan and translate text in 112 different languages.Whether you are a language learner, student with dyslexia, or a professional in need of quick translations for business or travel, this reading pen is the perfect tool for you. Simply scan any text with the pen and instantly see the translation on the screen. Say goodbye to flipping through dictionaries or struggling to understand foreign languages.
Don’t let language barriers hold you back – invest in the Translation Pen today and make communication a breeze wherever you go!
#Translation #Pen #OCR #Digital #Translator #Pen #Language #Learner #Portable #Wireless #Scan #Reader #PenReading #Pen #Dyslexia #Study #Business #Travel,peachloft language translatorLargest Genetic Study of Bipolar Disorder Identifies 298 Regions of the Genome That Increase Risk for the Condition
UNDER EMBARGO UNTIL
January 22 at 11:00 AM EST
Media Contact: Elizabeth Dowling
Mount Sinai Press Office
347-541-0212
[email protected]Largest Genetic Study of Bipolar Disorder Identifies 298 Regions of the Genome That Increase Risk for the Condition
Findings represent a four-fold increase over the last genome-wide association study conducted by an international consortium of leading psychiatric researchersNewswise — In the largest genome-wide study of bipolar disorder to date, an international team of psychiatric genetics researchers has identified 298 regions of the genome containing DNA variations that increase risk for the disorder—a more than four-fold increase over the number previously identified, according to research published in Nature [https://doi.org/10.1038/s41586-024-08468-9] on Wednesday, January 22.
The study—the first large multi-ancestry genomic analysis of the disorder to include data from people of European, East Asian, African American, and Latino ancestries—also identifies a new region associated with an increased risk for the disorder within the East Asian samples. Cross-referencing a range of methods, including fine-mapping and other variant-to-gene-mapping approaches, the team identified 36 genes suspected to be relevant to bipolar disorder. Bipolar disorder is an often lifelong mood disorder that impairs quality of life and functional ability, and is associated with suicidality. It affects an estimated 40-50 million people worldwide. Bipolar disorder is clinically heterogeneous, encompassing distinct subtypes 1 and 2. Bipolar disorder type 1 is characterized by episodes of both mania and depression, while bipolar disorder type 2 includes episodes of hypomania (a less severe form of mania) and depression. Despite the prevalence of bipolar disorder, it can take an average of eight years to get a proper diagnosis, and much remains unknown about the biology of the condition.
To help elucidate bipolar disorder’s underlying biology, an international team of scientists from within the Psychiatric Genomics Consortium conducted a genome-wide association study, scanning the DNA of 2.9 million study participants from cohorts worldwide to identify genetic markers that were more common in those with the condition. This involved scanning more than 6.7 million common variations in the DNA sequences among the study participants, more than 158,000 of whom experience bipolar disorder.
“It is well established that bipolar disorder has a substantial genetic basis, so identifying DNA variations that increase risk is of paramount importance to understanding the condition’s genetic architecture. In addition to identifying 298 regions of the genome that contain variations that increase risk for bipolar disorder, the 36 key genes we identified as being linked to the condition can now be followed up in a range of experiments to uncover the biological mechanisms through which each relates to the disorder,” says Niamh Mullins, PhD, Assistant Professor of Psychiatry, and Genetics and Genomic Sciences, at the Icahn School of Medicine at Mount Sinai and one of the senior authors of the paper. “The newly identified genes may also be used in experiments to explore new drug targets and drug development for bipolar disorder.”
The study team also found differences in the genetic characteristics of bipolar disorder between clinical (patients recruited from hospital inpatient or outpatient units), community-based (participants in general population biobanks), and self-reporting (participants in online personal health surveys) participants. These genetic differences are likely to be driven by a higher prevalence of bipolar subtype 1 in the clinical samples versus a higher prevalence of bipolar subtype 2 in the self-reporting samples, which highlights the need for researchers to be mindful of the data-gathering strategies used within their studies of the condition.
According to the research team, the genetic signal of bipolar disorder is related to specific brain cell types, including GABAergic interneurons and medium spiny neurons, in the prefrontal cortex and hippocampus. They also found that cells in the intestine and pancreas are involved, although more research is necessary to further understand this biology.
“Although this work does not immediately impact patient care, it opens the possibilities for long-term positive impact for patients and their families who are impacted by this widespread disorder,” said Ole Andreassen, MD, PhD, Professor of Psychiatry at the Institute of Clinical Medicine and Oslo University Hospital, and senior author of the paper. “Our research paves the way for the development of improved treatments, earlier interventions, and precision medicine approaches that will support clinicians in their decision-making to enable them to manage the condition in the most effective way for each patient.”
The Psychiatric Genomics Consortium (PGC) is an international consortium of scientists dedicated to studying the genetic basis of psychiatric disorders and includes more than 1,700 researchers from over 65 countries.
”This research would not have been possible without the collaborative efforts of scientists worldwide that enabled the study of hundreds of thousands of DNA sequences,” said Kevin O’Connell, PhD, researcher at the University of Oslo and first author of the paper.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report‘s® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
###
A groundbreaking study has revealed new insights into the genetic factors underlying bipolar disorder, a complex and often debilitating mental health condition. The largest genetic study of bipolar disorder to date has identified 298 regions of the genome that increase the risk for developing the disorder.Researchers from around the world analyzed genetic data from over 40,000 individuals with bipolar disorder and more than 60,000 controls without the condition. By comparing the genetic profiles of these two groups, the researchers were able to pinpoint specific regions of the genome that are associated with an increased risk for bipolar disorder.
The study, published in the journal Nature Genetics, sheds light on the genetic architecture of bipolar disorder and provides valuable information that could help researchers better understand the underlying mechanisms of the condition. By identifying these genetic risk factors, researchers hope to develop more targeted and effective treatments for individuals with bipolar disorder.
This groundbreaking study represents a major step forward in our understanding of the genetic basis of bipolar disorder. By identifying these 298 regions of the genome that increase the risk for the condition, researchers are paving the way for new discoveries and potential breakthroughs in the treatment of this complex disorder.
Tags:
- Bipolar disorder genetic study
- Genetic risk factors for bipolar disorder
- Genome regions and bipolar disorder
- Bipolar disorder genetic research findings
- Bipolar disorder risk factors
- Genetic study on bipolar disorder
- Bipolar disorder genetic markers
- Bipolar disorder genome regions
- Bipolar disorder genetic predisposition
- Bipolar disorder genetic analysis
#Largest #Genetic #Study #Bipolar #Disorder #Identifies #Regions #Genome #Increase #Risk #Condition
Ai Translating Earbuds, Wireless Bluetooth AI Translation Earbuds, Translation Pods Translator Earbuds, 144 Languages & Accents Translation for Business Office Travel Study (Black)
Price: $25.99
(as of Jan 23,2025 04:54:29 UTC – Details)
Product Description
Please download the APP on your mobile phone and scan the QR code in the user manual to download the APP
【Optimized for business use】 This translation device is designed for business and international communication, ensuring you can provide accurate information to customers and partners every time
【Real-time multi-language translation】 Experience seamless communication with our advanced translation technology, supporting real-time translation in 144 languages, perfect for international business interactions
【Stylish design】 Stylish appearance and comfortable design, with lightweight materials and ear-hook design, suitable for long-term wear without discomfort
【HI-FI sound quality】 Enjoy excellent sound quality during translation, allowing users to clearly hear and understand the translated content without any interference or misunderstanding
【Fast charging and long-lasting use】 With fast charging technology, this device can minimize charging time while maximizing usage time, ensuring that the translation tool is always available when you need it
Introducing the future of communication: Ai Translating Earbuds! These wireless Bluetooth AI Translation Earbuds are the perfect companion for business, office, travel, and study. With the ability to translate 144 languages and accents, these Translation Pods Translator Earbuds will revolutionize the way you interact with people from all around the world.Gone are the days of struggling to communicate in a foreign language. With these translation earbuds, you can easily converse with anyone, no matter what language they speak. Whether you’re in a meeting, traveling abroad, or studying in a new country, these earbuds will ensure that language barriers are a thing of the past.
The sleek black design of these earbuds makes them both stylish and functional. Simply connect them to your device via Bluetooth, select the language you want to translate, and start chatting away. The built-in AI technology ensures accurate and natural-sounding translations, so you can focus on what’s being said, rather than trying to decipher language differences.
Don’t let language stand in the way of your success. Invest in a pair of Ai Translating Earbuds today and experience the power of seamless communication.
#Translating #Earbuds #Wireless #Bluetooth #Translation #Earbuds #Translation #Pods #Translator #Earbuds #Languages #Accents #Translation #Business #Office #Travel #Study #Black,hyt26 translation earbuds
